A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female Population
- Registration Number
- NCT00534872
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The purpose of this study is to determine the blood levels and the tolerability of SB-649868 in Elderly and Female population
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description SB649868 SB-649868 10 mg
- Primary Outcome Measures
Name Time Method Blood levels after a single dose of SB-649868 after 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours single dose of SB-649868 after 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours
- Secondary Outcome Measures
Name Time Method Adverse Event, laboratory, vital signs and ECG abnormality occurred within 7-14 days from a single dose of SB-649868 within 7-14 days from a single dose of SB-649868
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of SB-649868 in targeting insomnia pathways in elderly and female populations?
How does SB-649868 compare to standard-of-care hypnotics in pharmacokinetic profiles and safety for insomnia treatment?
Which biomarkers correlate with SB-649868's pharmacokinetics and tolerability in non-childbearing potential females and elderly subjects?
What adverse events were observed in NCT00534872 and how do they inform SB-649868's safety profile in insomnia populations?
Are there combination therapies or competitor drugs with similar GABAergic mechanisms to SB-649868 for insomnia treatment in specific demographics?